The p53 tumor suppressor gene is a sequence-specific transcription factor that activates the expression of genes engaged in promoting growth arrest or cell death in response to genotoxic stress.

We next tested whether IFI 16 and p53 can interact while p53 is bound to DNA. Gel shift assays were performed using double stranded oligonucleotides derived from the p21 waf1/Cip1 promoter ...

An independent validation was performed on 914 patients. Nonmutational p53 dysfunction identifies MDS with poor outcomes that are not efficiently captured by conventional prognostic scores. These ...

What is the current share price of Vitasora Health Limited (VHL)? Vitasora Health Limited's (VHL) current share price is $0.04. This constitutes a price movement of 2.44% when compared to the share ...

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with ...

Nov. 25, 2021: VHL, VA (SI Sportsbook) is given the 13th sports betting license in VA. Nov. 24, 2021: The Virginia Lottery hands Digital Gaming Corporation (Betway) a temporary sports betting license.

The purpose of this study is to characterize the effectiveness of belzutifan for patients with VHL disease-associated RCC and/or CNS hemangioblastoma treated in real-world clinical practice. The ...

Cohort A1 of LITESPARK-015 trial included patients with advanced PPGL, cohort A2 included patients with pancreatic neuroendocrine tumors (pNETs), cohort B1 included patients with von Hippel-Lindau ...

sund.ku.dk Background Historically, the survival of patients with von Hippel-Lindau disease (vHL) has been poorer than that of the general population. We aimed to determine whether the survival of VHL ...

OBJECTIVES Central nervous system haemangioblastoma (HAB) is a major feature of von Hippel-Lindau (VHL) disease, and it is estimated that about 30% of HAB patients have VHL disease. Consequently, it ...

Several proteins have been studied in relation to the development and progression of colorectal cancer, including tumor protein p53 (p53) and antigen identified by monoclonal antibody Ki-67 (Ki-67).

Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma. The objective response rate (ORR) for belzutifan in patients with ...